Mazdutide: GLP-1/Glucagon Dual Receptor Agonist — Receptor Biology and Research Context

What Is Mazdutide?

• The glucagon-like peptide-1 receptor (GLP-1R) — expressed in pancreatic beta cells, the central nervous system, gastrointestinal tract, and cardiac tissue
• The glucagon receptor (GCGR) — expressed in hepatocytes, adipocytes, and the hypothalamus

This GLP-1R/GCGR dual agonism defines mazdutide's mechanistic position within the incretin/glucagon biology research space — distinct from the GLP-1R/GIPR (GIP receptor) dual agonism of tirzepatide, and a subset of the triple GLP-1R/GIPR/GCGR agonism of retatrutide.

Phase 1 Peptides supplies mazdutide as a research compound for laboratory use only.

Receptor Pharmacology

GLP-1 Receptor (GLP-1R) Arm

GLP-1 is an incretin hormone secreted by intestinal L-cells following nutrient ingestion. GLP-1R activation drives:

• Insulin secretion (glucose-dependent): Beta cell GLP-1R activation increases cAMP via Gαs, stimulating insulin exocytosis in a glucose-dependent manner — a mechanism that is pharmacologically self-limiting at euglycemic concentrations
• Glucagon suppression: GLP-1R signaling in alpha cells and via central circuits suppresses glucagon secretion, reducing hepatic glucose output
• Gastric motility: GLP-1R activation in the enteric nervous system and vagal afferents slows gastric emptying — an effect studied in gastrointestinal physiology models
• Central signaling: GLP-1R is expressed in the arcuate nucleus, nucleus of the solitary tract, and area postrema — regions involved in energy homeostasis regulation. Central GLP-1R agonism is studied in appetite-signaling and food-intake behavioral models

Glucagon Receptor (GCGR) Arm

Glucagon is a counter-regulatory hormone secreted by pancreatic alpha cells. GCGR activation in hepatocytes promotes glycogenolysis and gluconeogenesis — the primary mechanism for maintaining fasting glucose. Beyond hepatic glucose metabolism, GCGR activation has been studied for:

• Hepatic lipid metabolism: Published research has characterized GCGR-mediated upregulation of fatty acid oxidation pathways in hepatocytes and its effect on hepatic lipid accumulation in metabolic disease models
• Thermogenic pathway activity: GCGR is expressed in brown adipose tissue; research has examined glucagon's role in stimulating uncoupling protein (UCP1) expression and oxidative phosphorylation efficiency in thermogenic adipose models
• Energy expenditure: GCGR activation appears to offset the metabolic rate effects of GLP-1R-mediated gastric emptying reduction in dual-agonist designs — a mechanistic rationale cited in published literature for combining GLP-1 and glucagon activities in a single molecule

Why the GLP-1/GCGR Combination Is Studied

The GLP-1R/GCGR combination is mechanistically complementary in research designs because the two receptor axes address different downstream endpoints:

• GLP-1R agonism provides incretin-mediated insulin secretion and central signaling effects
• GCGR agonism adds hepatic lipid metabolism and thermogenic pathway engagement

The published rationale for co-activation is that these mechanisms may be synergistic in metabolic endpoint studies — GLP-1R-mediated glucose metabolism acting alongside GCGR-mediated hepatic and thermogenic effects.

Comparison: GLP-1–Based Dual and Triple Agonists in Research

Mazdutide occupies a distinct mechanistic niche: it is the primary published research tool for isolating the GLP-1R/GCGR dual-agonist axis, without GIP receptor involvement. This makes it useful in research designs that specifically want to study GLP-1/glucagon synergy without confounding GIPR activity.

For detail on the GLP-1R/GIPR combination, see the Tirzepatide vs. Semaglutide comparison. For triple agonism including GCGR, see the Retatrutide research primer.

Published Clinical Research Context

Mazdutide has been investigated in published Phase 2 and Phase 3 clinical trials for metabolic endpoints in study populations with type 2 diabetes and obesity-related metabolic conditions. Published trial datasets provide reference endpoints for:

• GH axis interaction through GCGR-mediated signaling
• Hepatic lipid parameters in subjects with metabolic liver disease
• GLP-1/glucagon axis modulation across different body mass index ranges

This clinical dataset makes mazdutide a useful published comparator in laboratory research examining how GLP-1R and GCGR interact at the receptor and downstream signaling level.

Laboratory Handling Notes

Mazdutide is a synthetic peptide supplied as a lyophilized powder. Reconstitution follows standard protocols using bacteriostatic water. Store lyophilized at −20 °C; reconstituted solutions at 2–8 °C. As a fatty-acid-conjugated peptide (designed for albumin binding), mazdutide should be reconstituted to complete dissolution before use. See the reconstitution guide and storage guide for standard protocols.

Product Availability

Phase 1 Peptides stocks Mazdutide at 99%+ purity with third-party laboratory documentation.

Both are dual GLP-1R agonists, but they pair GLP-1R with different second receptors. Tirzepatide co-activates the GIP receptor (GIPR) — the incretin receptor for glucose-dependent insulinotropic polypeptide, expressed in beta cells and adipocytes. Mazdutide co-activates the glucagon receptor (GCGR) — which drives hepatic glucose output and lipid oxidation pathways. The GCGR agonism in mazdutide engages thermogenic and hepatic lipid metabolism endpoints that GIPR agonism does not, while GIPR agonism in tirzepatide has distinct adipose biology effects. These mechanistic differences make them useful comparative tools in GLP-1 axis receptor biology research.

Retatrutide is a triple agonist at GLP-1R, GIPR, and GCGR simultaneously. Mazdutide is a dual GLP-1R/GCGR agonist without GIPR activity. In research designs, mazdutide allows isolation of GLP-1/glucagon dual-axis effects without confounding GIPR signal; retatrutide is used when the combined triple-receptor activation profile is the subject of study.

GCGR activation in hepatocytes increases cAMP via Gαs coupling, which promotes glycogenolysis, gluconeogenesis, and fatty acid oxidation gene expression (via PKA and CREB). In brown adipose tissue, GCGR signaling has been associated with upregulation of UCP1 (uncoupling protein 1) expression — the primary thermogenic effector in brown fat. These pathways are studied in published metabolic biology research as mechanisms by which glucagon contributes to energy substrate utilization beyond simple glycemic counterregulation.

For a side-by-side overview of all GLP-1R agonist research peptides including mazdutide, see the GLP-1 Receptor Agonist Research Landscape.

All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.